Erratum to "Preoperative Risk Factors for Failure After Fixed Sling Implantation for Postprostatectomy Stress Urinary Incontinence (FORESEE): A Systematic Review and Meta-analysis" [Eur. Urol. Open Sci. 77 (2025) 58-77] [0.03%]
“根治性前列腺切除术后经尿道植入固定吊带失败的术前风险因素（FORESEE）：系统评价和meta分析”一文的勘误表
Emilio Sacco,Marco Campetella,Filippo Marino et al.
Emilio Sacco et al.
[This corrects the article DOI: 10.1016/j.euros.2025.05.012.]. © 2025 The Author(s).
Published Erratum
European urology open science. 2025 Aug 6:81:96. DOI:10.1016/j.euros.2025.07.013 2025
Reply to Birhan Demirhan, Aysenur Elmali, and Cem Onal's Letter to the Editor re: Daniela E. Oprea-Lagera, Tessa van Elst, Shafak Aluwini, et al. How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View. Eur Urol Open Sci 2025; [0.03%]
关于Birhan Demirhan，Aysenur Elmali和Cem Onal的来信：Daniela E. Oprea-Lagera，Tessa van Elst，Shafak Aluwini等人。常规前列腺特异性膜抗原正电子发射断层扫描/ X线计算机体层摄影如何改变前列腺癌的当前管理？多学科观点回复欧罗尔-拉格拉等人的文章《常规前列腺特异性膜抗原正电子发射型断层扫描/ X线计算机体层摄影如何改变前列腺癌的现行管理策略？——多学科视角》（ Eur Urol Open Sci 2025）
Daniela Oprea-Lager,Tessa van Elst,Shafak Aluwini et al.
Daniela Oprea-Lager et al.
Efficacy and Safety of Mirabegron in Males with Overactive Bladder and Lower Urinary Tract Symptoms: Analysis from an Integrated Database [0.03%]
有效的安全性ミラベグラン治疗过量活跃的男性膀胱和下尿路症状：集成数据库分析
Farid Abdul Hadi,Arianne Schild,Merete Kock Hansen et al.
Farid Abdul Hadi et al.
Background and objective: Several phase 2-4 studies have investigated mirabegron for treating patients with overactive bladder (OAB). The objective of this study was to evaluate the efficacy and safety of mirabegron in ad...
In Defence of Context: Surrogates, Sequencing, and Real-world Evidence in Genitourinary Oncology [0.03%]
捍卫背景：泌尿生殖系统肿瘤中的替代终点、序贯证据和真实世界证据
Giandomenico Roviello,Silvia Mancini,Matteo Santoni
Giandomenico Roviello
Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis [0.03%]
恩fortumab vedotin治疗尿路上皮癌患者反应和生存的临床及分子预测因子：系统评价和meta分析
Mohammed Altenni,Péter Fehérvári,Jakub Hoferica et al.
Mohammed Altenni et al.
Background and objective: Enfortumab vedotin (EV) is emerging as a standard of care for advanced urothelial carcinoma (UC), but identification of which patients might benefit the most or least remains an unmet need. Our a...
Efficacy and Safety of Xialiqi for the Treatment of Benign Prostatic Hyperplasia in a Randomized Trial [0.03%]
夏荔芪治疗良性前列腺增生有效性和安全性的随机试验
Feiya Yang,Chao Yang,Xin Wang et al.
Feiya Yang et al.
Background and objective: Benign prostatic hyperplasia (BPH) is a major cause of lower urinary tract symptoms (LUTS) in men aged ≥50 yr. Xialiqi capsules are a traditional Chinese medicine mainly used for the treatment o...
Association of Sarcopenic Obesity with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms: A Nationwide Cross-sectional Study [0.03%]
sarcopenic肥胖症与良性前列腺增生/下尿路症状的关联：一项全国横断面研究
Zhonghan Zhou,Gongyue Liu,Junjie Ji et al.
Zhonghan Zhou et al.
Background and objective: This study explores the associations of sarcopenia, obesity, and their coexistence (sarcopenic obesity) with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). ...
Effectiveness and Safety of Mirabek Sustained-release 50 mg Tablets in Korean Patients with Overactive Bladder: A Multicenter Observational Study at Tertiary General Hospitals [0.03%]
甲磺酸默贝克缓释片（50mg）治疗中国患者膀胱过度活动症有效性和安全性的多中心观察研究
Jee Soo Park,Jongchan Kim,Moon-Hwa Park et al.
Jee Soo Park et al.
Background and objective: Mirabegron, a first-in-class β3-adrenergic agonist, is a key therapy for overactive bladder (OAB). This study aimed to evaluate the real-world effectiveness and safety of generic mirabegron (Mir...
Unlocking New Therapeutic Strategies in Oligometastatic Prostate Cancer with Radioligand and Metastasis-directed Radiation Therapy [0.03%]
放射配体和转移灶定向放疗在少部位多发性前列腺癌中的新治疗策略探讨
Salvatore Cozzi,Camille Roukoz,Thomas Zilli
Salvatore Cozzi
By delivering targeted radiation to tumor cells with a minimal impact on healthy tissues, radioligand therapy (RLT) has become an established treatment for metastatic castration-resistant prostate cancer. Its combination with external beam ...
Re: Shalender Bhasin, Peter J. Snyder. Testosterone Treatment in Middle-aged and Older Men with Hypogonadism. N Engl J Med 2025;393:581-91 [0.03%]
贝辛，斯奈德：中老年男子性腺功能减退的睾丸素治疗《新英格兰医学杂志》(2025;393:581-91)
Yu-Hsiang Lin,Jau-Yuan Chen,Chun-Te Wu
Yu-Hsiang Lin